Engineered immune cells take aim at stubborn blood cancers
NCT ID NCT06916767
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new type of CAR-T cell therapy called LMY-920 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to other treatments. The therapy uses a protein called BAFF to help the immune cells target and kill cancer cells. Up to 18 participants will receive a single infusion of these engineered cells, along with other drugs to prepare the body. The main goals are to find the safest dose and see if the treatment shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BAFF CAR-T cells (LMY-920) with obinutuzumab, cyclophosphamide, and fludarabine
- What this could lead to
- If it works, this could offer a new treatment option for people with CLL/SLL who have stopped responding to standard therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 18 participants, so it is too soon to know if it will be safe or effective. CAR-T therapy can cause serious side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY CLL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute
RECRUITINGCleveland, Ohio, 44195, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental antibody drug shows promise for Hard-to-Treat lymphoma
- Supercharged immune cells take on tough B-Cell cancers in early trial
- Card game aims to ease tough End-of-Life talks for cancer patients
- Targeted drug takes aim at NF1-Mutated cancers
- Targeted drug palbociclib tested against cancers with specific genetic flaw
- Engineered immune cells take on hard-to-treat lymphoma in early trial